| |
| |
|
| Insider
Information: |
Wasman Jane |
| Relationship: |
Director |
| City: |
Hawthorne |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
237,961 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$164,851 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
237,961 |
|
|
| Total
Value |
$164,851 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Acorda Therapeutics Inc |
ACOR |
President, Intl and GC |
2019-12-02 |
117,420 |
|
0 |
Premium* |
|
|
Rigel Pharmaceuticals Inc |
RIGL |
|
2023-05-26 |
75,000 |
2021-05-19 |
0 |
Premium* |
|
|
SELLAS Life Sciences Group Inc |
SLS |
Director |
2024-01-22 |
10,400 |
2022-01-31 |
0 |
Premium* |
|
|
Athersys Inc (New) |
ATHX |
Director |
2023-01-09 |
35,141 |
2022-09-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
82 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SLS |
SELLAS Life Sciences Grou... |
Director |
– • – |
2022-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
1,900 |
0 |
- |
|
| SLS |
SELLAS Life Sciences Grou... |
Director |
– • – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
4,400 |
0 |
- |
|
| SLS |
SELLAS Life Sciences Grou... |
Director |
– • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
10,400 |
0 |
- |
|
| ATHX |
Athersys Inc (New) |
Director |
– • – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,820 |
12,820 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2008-02-11 |
4 |
AS |
$22.90 |
$55,767 |
D/D |
(2,425) |
13,589 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2008-01-23 |
4 |
AS |
$22.30 |
$55,195 |
D/D |
(2,425) |
16,014 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2007-12-21 |
4 |
AS |
$20.50 |
$49,852 |
D/D |
(2,425) |
18,439 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2007-11-12 |
4 |
AS |
$18.57 |
$45,551 |
D/D |
(2,425) |
20,864 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2007-10-23 |
4 |
AS |
$19.95 |
$48,813 |
D/D |
(2,425) |
23,289 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2008-12-01 |
4 |
AS |
$15.98 |
$39,950 |
D/D |
(2,500) |
23,664 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2021-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2007-09-26 |
4 |
AS |
$18.56 |
$45,583 |
D/D |
(2,425) |
25,714 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2008-05-12 |
4 |
AS |
$19.00 |
$46,341 |
D/D |
(2,425) |
26,164 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2008-06-11 |
4 |
S |
$31.50 |
$110,420 |
D/D |
(3,500) |
26,164 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2007-08-10 |
4 |
AS |
$16.68 |
$41,307 |
D/D |
(2,425) |
28,139 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2008-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
28,589 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2008-06-11 |
4 |
OE |
$5.85 |
$20,475 |
D/D |
3,500 |
29,664 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2007-05-10 |
4 |
AS |
$24.13 |
$64,414 |
D/D |
(2,600) |
30,564 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2007-02-12 |
4 |
AS |
$21.07 |
$55,746 |
D/D |
(2,600) |
33,164 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2009-12-01 |
4 |
AS |
$24.50 |
$122,507 |
D/D |
(5,000) |
33,664 |
0 |
- |
|
| ATHX |
Athersys Inc (New) |
Director |
– • – |
2023-01-09 |
4 |
A |
$0.00 |
$0 |
D/D |
22,321 |
35,141 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2006-11-10 |
4 |
AS |
$15.13 |
$73,612 |
D/D |
(4,851) |
35,764 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2009-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
38,664 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2006-11-07 |
4 |
AS |
$14.89 |
$1,489 |
D/D |
(100) |
40,615 |
0 |
- |
|
| ACOR |
Acorda Therapeutics Inc |
Exec VP, General Counsel & Sec |
• – – |
2006-11-07 |
4 |
AS |
$14.91 |
$102,197 |
D/D |
(6,700) |
40,715 |
0 |
- |
|
82 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
